New Drugs for the Treatment of Lymphoma

Luca Paoluzzi, Yukiko Kitagawa, Matko Kalac, Jasmine Zain, Owen A. O'Connor

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Historically, most drugs developed for treatment of leukemias, lymphomas, and myeloma had already been studied in the solid tumor setting. Nearly 10 years ago, chronic myelogenous leukemia (CML) forever changed this paradigm. Imatinib showed that it was possible to nullify the pathognomic genetic lesion in a hematologic malignancy. Since the approval of imatinib for CML, a host of new drugs active in blood cancers have emerged. This article highlights some areas of innovative drug development in lymphoma where possible; it emphasizes the biologic basis for the approach, linking this essential biology to the biochemical pharmacology. The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway.

Original languageEnglish (US)
Pages (from-to)1007-1035
Number of pages29
JournalHematology/Oncology Clinics of North America
Volume22
Issue number5
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Keywords

  • Bcl-2
  • Lymphoma
  • New drugs
  • Pralatrexate
  • Syk

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'New Drugs for the Treatment of Lymphoma'. Together they form a unique fingerprint.

  • Cite this